Leukaemia - chronic myelomonocytic leukaemia

The PBS subsidises azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with azacitidine under the National Health Act 1953, section 100 and subsidises treatment with decitabine+cedazuridine under the National Health Act 1953, section 85 for patients with CMML.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing azacitidine and decitabine+cedazuridine.

Section 100 arrangements

Azacitidine

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised azacitidine to treat CMML can be made either in:

All written applications must include the completed:

Applications for initial authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat CMML can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised azacitidine to treat CMML can be made either:

Applications for continuing authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat CMML can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information on azacitidine.

Call the PBS Authority Approvals enquiry line for more information on decitabine+cedazuridine.

Page last updated: 4 October 2022